Premier Research Sees Growth Once Again
Premier Research achieves double-digit growth in functional sourcing for the third straight year.
Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
PHILADELPHIA, Nov. 4 /PRNewswire/ -- Premier Research Group Limited, the international pharmaceutical services group, reports that its Functional Sourcing group has seen a 70 percent growth in its labor force for the current fiscal year, representing a continued trend in its third straight year with high double-digit growth. This growth has included:
-- Doubling the number of functional sourcing agreements with Top 20
pharmaceutical companies as ranked by Contract Pharma in 2008
-- Selection as sole provider of functionally sourced data management
activities for a Top 5 Pharma in support of recent biotech acquisition
-- Exceeding the anticipated 2008 study lock goals by the third quarter
Keith Fine, Senior Director of Premier Research's Functional Sourcing activities indicated that "the growth is largely attributed to an increasing demand for outsourcing on a functional basis in the industry. Sponsors are recognizing Premier Research's leadership in this area and are impressed with the model we employ and the quality we deliver. Much of the growth we have realized is with our current partners."
Premier Research provides Functional Sourcing solutions in a wide array of services and therapeutic areas to pharmaceutical and biotech companies worldwide. The unique model developed and implemented at Premier Research allows sponsors to leverage Premier Research's expertise within clinical research as well as the international depth of our resource pool.
About Premier Research
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for analgesia, CNS, oncology, and infectious disease and have a wealth of experience in medical device and pediatric research. Premier Research has 30 offices and operates in more than 30 countries across North America and Europe. They employ a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at a well-established network of dedicated clinical sites.
http://www.premier-research.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
